Successful Management of BRAF V600E-Mutated Metastatic Colorectal Cancer With Liver Dysfunction Using Encorafenib-Based Therapy
{{output}}
The recent approval of encorafenib, cetuximab, and FOLFOX based on the phase III BREAKWATER trial has introduced a new standard of care for the first-line treatment of BRAF V600E-mutated metastatic colorectal cancer (mCRC). However, its safety and efficacy in ... ...
